No. 4 · Finance · 16 November 2026
Zoetis leaned on livestock as pets slipped
Dogs and cats fell 6% in the third quarter while every livestock species grew, poultry included. Livestock replaced 60% of what pets lost.
Tap the exhibit to open it at full size.
Zoetis reported third quarter revenue of US$2.39 bn, 1% below 3Q25. Profit fell more steeply, yet the company raised its full year profit guidance.
Pet sales fell. Companion animal revenue dropped 5% to US$1,565 m. The weakness was in the United States, where companion animal sales fell 8% to US$980 m; Zoetis attributes this to price sensitive pet owners, competitive pressure in canine dermatology, home of its itch treatments Apoquel (oclacitinib) and Cytopoint (lokivetmab), and generic competition. Outside the United States the same category grew 1%.
Livestock filled most of the gap. Livestock revenue rose 7% to US$797 m, adding US$51 m against a companion animal decline of US$85 m, and its share of company revenue moved from 31% to 33%. Cattle, at US$439 m, is more than half of the livestock line and grew 6%. Fish, where Zoetis's PHARMAQ business sells vaccines for farmed fish such as salmon, grew 23%.
Livestock has grown faster than pets for five quarters. Livestock revenue has grown faster than companion animal revenue in every quarter since 3Q25. Growth here is measured against the same quarter a year earlier, excluding currency and the medicated feed additives Zoetis sold to Phibro in October 2024. In the eleven quarters before 3Q25, livestock led only once, in 1Q23, when pet sales were flat. Most of the change came from pets. Companion animal growth averaged 12% a quarter from 4Q22 to 3Q24 and −2% over the last five quarters, a fall of 14 points. Over the same periods livestock growth rose from 6% to 10%, a gain of 4 points.
The lead is in growth only. In 3Q26 livestock revenue was US$797 m, about half the US$1,565 m from dogs and cats. The difference between the two growth rates peaked at 17 points in 2Q26 and narrowed to 12 points in 3Q26, as livestock growth slowed from 11% to 7%. One quarter is flattered. In 2026 Zoetis aligned the financial year of some international operations, which it says added about US$100 m to 1Q26 revenue, mostly outside the United States, where most of its livestock sales are made. Including currency and the divested products, the run starts in 4Q25 and is four quarters long.
Poultry grew 2%. Poultry revenue was US$108 m, the slowest growth among the livestock lines in the quarter. Over nine months the picture is stronger, at US$341 m, 8% above the same period of 2025, or 7% excluding currency. Zoetis names poultry among the lines that grew in the United States but gives no detail by product or market. Poultry is 4.5% of Zoetis revenue and about one seventh of its livestock business.
Profit fell faster than sales. Adjusted net income, which excludes acquisition accounting and special items, fell 5% to US$720 m. Net income fell 18% to US$591 m, after US$133 m of special items against US$8 m a year earlier; the largest was a US$89 m write down, mostly on research assets acquired with PetMedix in 2023. Earnings per share still rose 3% on an adjusted basis, because share buybacks have cut the share count by 7% in a year.
Growth came from the lower margin segment. Gross margin, the share of revenue left after the cost of making the products, is 82% in the United States segment and 69% in International. United States segment earnings fell 8% to US$830 m while International rose 7% to US$600 m.
Guidance. Zoetis narrowed its 2026 revenue guidance to US$9.22 bn to US$9.32 bn (previously US$9.12 bn to US$9.32 bn), a decline of 1% to 2% excluding currency and acquisitions, and raised its adjusted net income guidance to US$2.60 bn to US$2.64 bn.
The Ulnus read
For a decade, pets drove growth in animal health. At Zoetis, farm animals have done so since the third quarter of 2025. Because most of the shift came from pets slowing, a recovery in pet sales would close much of the gap. Dogs and cats remain 62% of Zoetis revenue, so the mix shifts slowly, and livestock customers are now where the largest animal health company earns its growth, which usually brings more attention to them in products, field support and price. For poultry, the quarter was quiet, with modest growth and no product news.
Source: Zoetis, Third Quarter 2026 Results (5 November 2026); quarterly results since February 2023. Ulnus analysis.
About this analysis. Ulnus may use artificial intelligence tools to extract and process source data, run calculations and draft commentary. All such work is directed, reviewed and approved by Ulnus, and every figure is checked against the cited source before publication. The analysis and conclusions are those of Ulnus. This content is provided for information only and does not constitute investment advice.